Edition:
United States

Idera Pharmaceuticals Inc (IDRA.OQ)

IDRA.OQ on NASDAQ Stock Exchange Capital Market

2.23USD
22 Sep 2017
Change (% chg)

$-0.03 (-1.33%)
Prev Close
$2.26
Open
$2.25
Day's High
$2.28
Day's Low
$2.20
Volume
144,134
Avg. Vol
173,472
52-wk High
$3.31
52-wk Low
$1.30

Latest Key Developments (Source: Significant Developments)

Idera Pharmaceuticals Q2 loss per share $0.14
Monday, 7 Aug 2017 05:00pm EDT 

Aug 7 (Reuters) - Idera Pharmaceuticals Inc :Q2 loss per share $0.14.Q2 earnings per share view $-0.11 -- Thomson Reuters I/B/E/S.Idera Pharmaceuticals Inc - ‍as of June 30, 2017, our cash, cash equivalents and investments totaled $77.2 million​.Idera Pharmaceuticals Inc - ‍currently anticipate our cash position is capable of funding our operations into Q4 of 2018​.  Full Article

FDA gives "orphan drug" status to Idera's skin cancer drug
Thursday, 22 Jun 2017 04:30pm EDT 

June 22 (Reuters) - Idera Pharmaceuticals Inc -:Idera announces FDA orphan drug designation for IMO-2125 for the treatment of melanoma.Idera Pharmaceuticals Inc - expects to complete enrollment of phase 2 multicenter trial in h2 2017, overall response rate data available in q1 of 2018.Idera Pharmaceuticals - company recently initiated a trial of imo-2125 monotherapy in refractory solid tumors, including pd-1 refractory melanoma.Idera Pharmaceuticals - enrolling second arm in phase 1/2 clinical trial in patients with pd-1 refractory melanoma to study imo-2125 and pembrolizumab.  Full Article

Idera Pharmaceuticals reports Q1 loss per share $0.10
Thursday, 4 May 2017 04:01pm EDT 

May 4 (Reuters) - Idera Pharmaceuticals Inc :Idera Pharmaceuticals reports first quarter 2017 financial results and provides corporate update.Q1 loss per share $0.10.Q1 earnings per share view $-0.10 -- Thomson Reuters I/B/E/S.Qtrly Alliance revenue $ 378,000 versus $294,000.  Full Article

Idera Pharmaceuticals reports Q4 earnings per share $0.01
Wednesday, 15 Mar 2017 04:30pm EDT 

Idera Pharmaceuticals Inc : Idera Pharmaceuticals reports fourth quarter and year end 2016 financial results and provides corporate update . Q4 earnings per share $0.01 .Q4 earnings per share view $-0.11 -- Thomson Reuters I/B/E/S.  Full Article

Idera Pharma reports positive Phase 1 data for IMO-2125
Friday, 24 Feb 2017 11:30am EST 

Idera Pharmaceuticals Inc : Idera Pharmaceuticals presents update from ongoing phase 1 dose escalation clinical trial of Intratumoral IMO-2125 in combination with Ipilimumab in metastatic melanoma patients refractory to Anti-PD-1 treatment at the 2017 ASCO-SITC clinical Immuno-Oncology Symposium . Have achieved successful completion of all our objectives in phase 1 portion of the trial .Undertaking a parallel development pathway for IMO-2125 in combination with Pembrolizumab.  Full Article

Baker Bros. Advisors LP reports 7.2 pct stake in Idera Pharmaceuticals - SEC filing
Tuesday, 11 Oct 2016 05:33pm EDT 

Baker Bros. Advisors LP:Baker Bros. Advisors LP reports 7.2 percent stake in Idera Pharmaceuticals Inc as of Oct. 7 - sec filing.  Full Article

Idera Pharmaceuticals says public offering of 25 mln common shares priced at $2.00 per share
Friday, 7 Oct 2016 09:04am EDT 

Idera Pharmaceuticals Inc : Idera Pharmaceuticals announces pricing of public offering of common stock .Says public offering of 25.0 million common shares priced at $2.00per share.  Full Article

Idera Pharma says announces proposed public offering of common stock
Wednesday, 5 Oct 2016 04:00pm EDT 

Idera Pharmaceuticals : Idera pharmaceuticals inc says intends to offer and sell up to $50,000,000 of shares of its common stock in an underwritten public offering . Idera pharmaceuticals announces proposed public offering of common stock . Idera pharmaceuticals inc says intends to offer and sell up to $50 million of shares of its common stock in an underwritten public offering .Intends to use net proceeds from offering to advance clinical development of certain of its programs.  Full Article

Idera Pharmaceuticals Q2 loss per share $0.11
Tuesday, 2 Aug 2016 07:00am EDT 

Idera Pharmaceuticals Inc : Q2 loss per share $0.11 . Q2 revenue $300,000 . Idera Pharmaceuticals reports second quarter 2016 financial results and provides corporate update . Q2 earnings per share view $-0.11 -- Thomson Reuters I/B/E/S .Q2 revenue view $142,000 -- Thomson Reuters I/B/E/S.  Full Article

Idera Pharmaceuticals reports Q1 loss per share $0.11
Monday, 9 May 2016 04:00pm EDT 

Idera Pharmaceuticals Inc : Idera pharmaceuticals reports first quarter 2016 financial results and provides corporate update . Q1 loss per share $0.11 .Q1 earnings per share view $-0.11 -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-Idera Pharmaceuticals files for‍​ mixed shelf

* Idera pharmaceuticals inc files for‍​ mixed shelf of up to $250 million - sec filing‍​ Source text for Eikon: Further company coverage: